jcm-logo

Journal Browser

Journal Browser

Prostate Surgery: The Latest Advances and Future Trends

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".

Deadline for manuscript submissions: 20 April 2026 | Viewed by 423

Special Issue Editors


E-Mail Website
Guest Editor
Department of Urology, University of California, Irvine, CA 92868, USA
Interests: urology; minimally invasive treatments for benign prostatic hyperplasia (BPH); endoscopic laser surgery; lower urinary tract dysfunction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor Assistant
Department of Urology, University of California, Irvine, UK
Interests: ultrasound and fluoroscopic guided percutaneous nephrolithotomy (PCNL); laser enucleation (HoLEP); single-port and multi-port robotic-assisted renal surgery; complex ureteroscopy; laparoscopy and general urology

Special Issue Information

Dear Colleagues,

The field of benign prostatic hyperplasia (BPH) surgery has undergone remarkable advancements over the past few decades. Traditional transurethral resection of the prostate (TURP) has long been the gold standard; however, the rise in minimally invasive techniques and modern technology has significantly transformed patient care. Innovations such as laser enucleation, water-based ablation, and novel implants have led to better outcomes with reduced complications and faster recovery.

This Special Issue aims to explore the latest breakthroughs in BPH surgical management, highlighting both established and emerging technologies. By bringing together experts in the field, we seek to provide a comprehensive overview of current trends and future directions, including minimally invasive surgical therapies (MIST), anatomic enucleation techniques, robotic-assisted procedures, precision-guided therapies, and novel biomaterials.

We invite original research, systematic reviews, and clinical studies that focus on cutting-edge technologies such as holmium and thulium laser enucleation, Aquablation, Rezum, iTIND, UroLift, prostate artery embolization (PAE), robotic simple prostatectomy, and novel BPH technologies. Papers discussing advancements in long-term outcomes are also encouraged.

You may choose our Joint Special Issue in Uro.

Dr. Akhil K. Das
Guest Editor

Dr. Bruce Gao
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • benign prostatic hyperplasia (BPH)
  • minimally invasive surgical therapies (MIST)
  • laser enucleation (HoLEP, ThuLEP)
  • Aquablation
  • Rezum
  • robotic prostatectomy
  • anatomic enucleation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

9 pages, 750 KB  
Brief Report
A Case Series on the Efficacy and Safety of Transperineal Laser Ablation for Benign Prostatic Hyperplasia
by Malone R. Locke and Donald Russell Locke
J. Clin. Med. 2026, 15(2), 540; https://doi.org/10.3390/jcm15020540 - 9 Jan 2026
Viewed by 95
Abstract
Background/Objectives: Traditional surgeries for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), carry risks including sexual dysfunction and extended recovery. EchoLaser transperineal laser ablation (TPLA) offers a minimally invasive alternative with potential benefits in preserving sexual function and [...] Read more.
Background/Objectives: Traditional surgeries for benign prostatic hyperplasia (BPH), such as transurethral resection of the prostate (TURP), carry risks including sexual dysfunction and extended recovery. EchoLaser transperineal laser ablation (TPLA) offers a minimally invasive alternative with potential benefits in preserving sexual function and reducing recovery time. This exploratory study evaluated the safety and efficacy of EchoLaser TPLA for the treatment of prostate-related voiding symptoms. Methods: This retrospective, single-center study enrolled seven patients with lower urinary tract symptoms due to BPH. TPLA was performed under local anesthesia, and follow-up was conducted at 1, 3, 6, and 12 months. The primary outcome was measured by the International Prostate Symptom Score (IPSS). Secondary outcomes included PSA levels, prostate and transition zone (TZ) volume, Qmax, post-void residual (PVR) volume, quality of life (QoL) score, Sexual Health Inventory for Men (SHIM) score, and Male Sexual Health Questionnaire to assess for ejaculatory dysfunction (MSHQ-EjD) score. Results: Statistically significant improvements in IPSS, Qmax, PVR, and QoL relative to baseline were observed at 1 month post-treatment, and these improvements remained significant throughout the 12-month follow-up period. Post-treatment reductions in PV and TZ volume were statistically significant at 6 months; while PV was further reduced at 12 months, this change lacked statistical significance. No statistically significant post-treatment changes were observed in SHIM, MSHQ-EjD 3-Item or Bother scores, or PSA. Mean pain score on the 10-point visual analog scale for procedural pain was 2.14 ± 0.69. Conclusions: Although limited by a lack of generalizability, our findings are consistent with previous studies that have shown EchoLaser TPLA to be a safe and effective in-office treatment for prostate-related voiding symptoms, with minimal discomfort and negligible impact on sexual function. Further studies with larger cohorts and extended follow-up are needed. Full article
(This article belongs to the Special Issue Prostate Surgery: The Latest Advances and Future Trends)
Show Figures

Figure 1

Back to TopTop